Clinical trial
New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study (NAVIG-1)
NCT06622434 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study (NAVIG-1)
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- November 8, 2024
- Completion date
- March 8, 2028
- Enrollment
- 35 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
newly diagnosed glioblastoma